GlassScriptPhysician profile
Tania E Anderson
NPI 1619948544
$18,335.63
in general payments reported to CMS, 2019-2025
57 companies · $4,079 in 2025
The $4,079 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,954 · 2020: $1,835 · 2021: $2,394 · 2022: $1,872 · 2023: $2,300 · 2024: $2,902 · 2025: $4,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,280.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,323.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $2,234.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,640.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,555.16 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $1,303.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,170.50 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,029.80 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $920.94 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $887.10 | 2019-2024 | Xarelto, Spotlight |
| Otsuka America Pharmaceutical, INC. | $448.35 | 2020-2025 | Rexulti |
| Amarin Pharma, INC. | $426.21 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $398.13 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $269.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $261.79 | 2019-2021 | |
| Exact Sciences Corporation | $244.25 | 2023-2025 | Cologuard Collection Kit |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tania Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.